Toth Financial Advisory Corp Buys Shares of 3,205 DaVita Inc. $DVA

Toth Financial Advisory Corp purchased a new stake in DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,205 shares of the company’s stock, valued at approximately $713,000.

Several other large investors have also bought and sold shares of the business. Fifth Third Bancorp raised its holdings in DaVita by 831.4% during the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in DaVita by 30.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after purchasing an additional 10,477 shares in the last quarter. SG Americas Securities LLC increased its position in shares of DaVita by 27.4% during the 1st quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after purchasing an additional 45,609 shares during the period. Invst LLC acquired a new position in shares of DaVita during the 2nd quarter valued at $1,238,000. Finally, LSV Asset Management raised its stake in shares of DaVita by 1.1% in the 4th quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after buying an additional 9,739 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Stock Up 1.0%

Shares of NYSE DVA opened at $180.72 on Friday. The stock’s fifty day simple moving average is $211.96 and its 200 day simple moving average is $183.05. The stock has a market capitalization of $11.53 billion, a price-to-earnings ratio of 14.79, a PEG ratio of 0.46 and a beta of 0.88. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the prior year, the business posted $2.95 earnings per share. DaVita’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current year.

Analyst Ratings Changes

DVA has been the subject of several research reports. Raymond James Financial set a $220.00 target price on DaVita in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Barclays raised their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 5th. UBS Group lifted their price objective on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Truist Financial dropped their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, DaVita presently has a consensus rating of “Hold” and an average price target of $221.75.

Insider Buying and Selling

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider directly owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.90% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.